Intellia Therapeutics (NASDAQ:NTLA) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, August 1st. Analysts expect Intellia Therapeutics to post earnings of ($0.61) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.
Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($0.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.53) by $0.04. The business had revenue of $10.43 million during the quarter, compared to the consensus estimate of $9.43 million. Intellia Therapeutics had a negative net margin of 257.28% and a negative return on equity of 31.68%. The firm’s quarterly revenue was up 39.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.51) EPS. On average, analysts expect Intellia Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Shares of NASDAQ:NTLA traded down $0.18 during mid-day trading on Wednesday, hitting $18.33. The stock had a trading volume of 52,362 shares, compared to its average volume of 487,040. The company has a current ratio of 7.74, a quick ratio of 7.74 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $850.21 million, a P/E ratio of -9.26 and a beta of 2.62. Intellia Therapeutics has a 12-month low of $11.03 and a 12-month high of $32.95. The firm’s 50 day simple moving average is $16.06.
Several equities research analysts recently commented on NTLA shares. Chardan Capital restated a “buy” rating and issued a $57.50 price target on shares of Intellia Therapeutics in a research report on Tuesday, May 28th. Robert W. Baird started coverage on shares of Intellia Therapeutics in a research report on Monday, July 8th. They issued an “outperform” rating and a $23.00 price target for the company. BidaskClub upgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, June 20th. Roth Capital started coverage on shares of Crispr Therapeutics in a research report on Monday, June 10th. They issued a “buy” rating and a $50.00 price target for the company. Finally, Evercore ISI started coverage on shares of Homology Medicines in a research report on Thursday, April 11th. They issued an “outperform” rating and a $29.00 price target for the company. Eight analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $25.31.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.